A Look Back at 2022 FDA Approvals in Oncology
In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.
In this special episode of The Vitals, we ring in the New Year 2023 by combing through 2022 FDA approvals. Listen as associate editor, Lindsay Fischer, recounts key approvals on a month-by-month basis, with input from some of the investigators from behind the research. To read the full information surrounding the approvals, be sure to check out our news coverage below. Other resources can also be found below.
As always, thank you for listening to The Vitals, and for all the engagement in 2022. We look forward to bringing you more oncology news in 2023.
We want to hear from you! Which drugs approved in 2022 have been practice changing? Have you had any difficulty or success in incorporating these novel agents into clinical use? Any challenges with supporting patients on these regimens? Email lfischer@mjhlifesciences.com with your feedback
References
January
February
March
- Neoadjuvant Nivolumab Plus Platinum-Doublet Chemotherapy Is Now Approved for Resectable NSCLC
- FDA Greenlights Olaparib for BRCA-Mutated, HER2-Negative Breast Cancer
- FDA OKs Relatlimab/Nivolumab for Unresectable or Metastatic Melanoma
- FDA Approves Pembrolizumab in MSI H/dMMR Advanced Endometrial Carcinoma
- FDA Approves 177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
April
May
- FDA Approves Trastuzumab Deruxtecan for Unresectable or Metastatic HER2+ Breast Cancer
- FDA Grants Ivosidenib Plus Azacitidine Approval for Newly Diagnosed AML With IDH1 Mutations
- FDA Grants Azacitidine Approval For Pediatric Patients With Myelomonocytic Leukemia
- FDA Grants 2 Frontline Nivolumab-Based Regimens Approval for Unresectable Advanced or Metastatic ESCC
- Tisagenlecleucel Receives FDA Approval for Relapsed or Refractory Follicular Lymphoma
June
- FDA Grants Accelerated Approval to Dabrafenib Plus Trametinib for BRAF V600E–Mutated Solid Tumors
- FDA Approves Liso-Cel for Second-Line Large B-Cell Lymphoma
July
August
- HER2-Directed Therapy, Trastuzumab Deruxtecan, Approved for Metastatic NSCLC
- Trastuzumab Deruxtecan Is Approved for Patients With Metastatic HER2-Low Breast Cancer
- FDA Approves Darolutamide Tablets for Select Patients With Prostate Cancer
- Capmatinib Snags Full FDA Approval for MET Exon 14 Skipping NSCLC
- FDA Grants Ibrutinib Approval for Pediatric Graft-Versus-Host-Disease
- FDA Gives Pemigatinib Greenlight for FGFR1 Rearranged Myeloid/Lymphoid Neoplasms
September
- Durvalumab Plus Gemcitabine/Cisplatin Approved by the FDA for Advanced or Metastatic Biliary Tract Cancers
- Sodium Thiosulfate Gets Green Light for Chemotherapy-Induced Hearing Loss in Pediatric Patients
- Selpercatinib Is Approved for 2 RET Fusion–Positive Solid Tumors, Non–Small Cell Lung Cancer
- FDA Approves Futibatinib for Pretreated, Advanced or Metastatic Intrahepatic Cholangiocarcinoma with FGFR2 Rearrangements
October
- FDA Approves Durvalumab in Combination with Tremelimumab for Unresectable HCC
- Teclistamab-cqyv Snags Accelerated Approval for Relapsed or Refractory Multiple Myeloma
November
- Cemiplimab Gets Go Ahead In Combination With Chemotherapy For Advanced NSCLC
- Brentuximab Vedotin Gets Green Light for High-Risk Hodgkin Lymphoma in Pediatric Patients
- Durvalumab/Tremelimumab/Chemotherapy Combination Approved for NSCLC Indication
- Mirvetuximab Soravtansine-gynx Gets Go Ahead in Platinum-Resistant Ovarian Cancer
December
- Olutasidenib Approved for IDH1-Mutated Acute Myeloid Leukemia
- Adagrasib Receives Accelerated Approval for KRAS G12C Mutated NSCLC
Additional Resources:
Videos
- Watch: Newly Approved Tebentafusp Requires Up-Front Active Toxicity Management in Melanoma
- Dr. Geyer Highlights Optimal Dosing Strategies for New Olaparib Indication in Breast Cancer
- Nurse Takeaways: Latest Pembrolizumab Indication in Endometrial Cancer
Oncology Nursing News® Online Articles
- Podsada Discusses Biomarker Testing and ADC Therapies in Breast Cancer
- Goodwin Provides Nursing Perspective on Recent FDA Approvals in NSCLC
- Futibatinib Approval Ushers in Targeted Therapy Option for Patients With Unresectable, Intrahepatic FGFR2-Positive Cholangiocarcinoma
- Barber Discusses the Integration of Durvalumab/Chemotherapy Combination as New Standard of Care in Biliary Tract Cancers
The Vitals Podcast:
